The worldwide increase of obesity and type 2 diabetes is taking on pandemic proportions. According to current estimates, more than 366 million people have diabetes, and this is expected to reach 552 million by 2030. Regarding 2008 WHO global estimates, around 12% of adults aged 20 years or more are obese. Even more alarming is the rate of increase in childhood obesity, which has more than doubled in children and tripled in adolescents in the past 30 years.
Importantly, this may evolve to an excessive burden of morbidity and mortality due to an expected increase in their long-term complications: cardiovascular disease, retinopathy, neuropathy, kidney and liver diseases, cancer, depression, impaired quality of life, etc. Moreover, this picture is further complicated by the fact that obesity and diabetes are interrelated: obesity is associated with insulin resistance (a risk factor for type 2 diabetes) and may precede diabetes, and also obesity is observed in an important number of diabetic patients. The term Diabesity has been coined to describe the concomitant presence of both diseases and their pathogenic association.
This represents a major challenge in nephrology since a considerable number of the population with diabesity may develop complications such as albuminuria, overt proteinuria and decreasing renal function which untreated may lead to end-stage renal disease. Importantly, the pathogenetic pathways of how obesity causes renal disease are unknown. Furthermore, patients with diabetic nephropathy are at highly increased risk of cardiovascular morbidity and mortality.
The following specific themes will be developed in order to extend scientific knowledge and understanding:
|2||F.Y.R. OF MACEDONIA|